Novartis AG Other Operating Income or Expenses 2012-2026 | NVS

Novartis AG annual/quarterly other operating income or expenses history and growth rate from 2012 to 2026. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
  • Novartis AG other operating income or expenses for the quarter ending March 31, 2026 were $50M, a 116.34% decline year-over-year.
  • Novartis AG other operating income or expenses for the twelve months ending March 31, 2026 were $-0.527B, a 68.61% decline year-over-year.
  • Novartis AG annual other operating income or expenses for 2025 were $-0.883B, a 49.91% decline from 2024.
  • Novartis AG annual other operating income or expenses for 2024 were $-1.763B, a 232.02% increase from 2023.
  • Novartis AG annual other operating income or expenses for 2023 were $-0.531B, a 79.32% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Novartis AG Annual Other Operating Income or Expenses
(Millions of US $)
2025 $-883
2024 $-1,763
2023 $-531
2022 $-2,568
2021 $-895
2020 $-1,448
2019 $-1,395
2018 $-980
2017 $-362
2016 $-417
2015 $-824
2014 $-1,121
2013 $-842
2012 $-893
2011 $-1,980
Novartis AG Quarterly Other Operating Income or Expenses
(Millions of US $)
2026-03-31 $50
2025-12-31 $-30
2025-09-30 $-66
2025-06-30 $-481
2025-03-31 $-306
2024-12-31 $-361
2024-09-30 $-785
2024-06-30 $-227
2024-03-31 $-390
2023-12-31 $-161
2023-09-30 $-197
2023-06-30 $-201
2023-03-31 $28
2022-12-31 $-662
2022-09-30 $-605
2022-06-30 $-1,027
2022-03-31 $-274
2021-12-31 $-590
2021-09-30 $-198
2021-06-30 $253
2021-03-31 $-360
2020-12-31 $88
2020-09-30 $-808
2020-06-30 $-32
2020-03-31 $-696
2019-12-31 $-143
2019-09-30 $-600
2019-06-30 $-319
2019-03-31 $-333
2018-12-31 $-586
2018-09-30 $-276
2018-06-30 $-22
2018-03-31 $-84
2017-12-31 $-62
2017-09-30 $-95
2017-06-30 $-88
2017-03-31 $-117
2016-12-31 $-240
2016-09-30 $-80
2016-06-30 $-296
2016-03-31 $199
2015-12-31 $-221
2015-09-30 $-210
2015-06-30 $-305
2015-03-31 $-88
2014-12-31 $-85
2014-09-30 $-414
2014-06-30 $-383
2014-03-31 $-239
2013-12-31 $-192
2013-09-30 $-332
2013-06-30 $-129
2013-03-31 $-189
2012-12-31 $-222
2012-09-30 $-239
2012-06-30 $-188
2012-03-31 $-244
2011-12-31 $-1,453
2011-09-30 $-434
2011-06-30 $-143
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $293.951B $54.532B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88